SIRPA and diffuse large B-cell lymphoma: While most ICI combinations focus on T‐cell effector function, inhibitors of the macrophage/myeloid cell checkpoint via the CD47/SIRPα axis are also being studied as a combination partner to further enhance the efficacy of DLBCL immunotherapy.